65,437 trials
Schizophrenia
Primary: Change From Baseline in PANSS Total Score at the End of the Double-blind Treatment Phase (Week 6 or the Last Assessment Obtained After the Baseline Assessment). — -11.7…
Infertility
Primary: Number of Participants With an Ongoing Pregnancy — 14; 13 participants
Pneumonia
Primary: Clinical Cures in the Intent to Treat Population — 217; 206; 14; 13 Participants — p=0.5667
Early Rheumatoid Arthritis
Primary: Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 52 — 118; 113; 165 participants — p=<0.001
Human Papillomavirus Infection
Primary: Geometric Mean Antibody Titers Following the Third Dose of Human Papilloma Virus (HPV) Vaccine by Virus Type and by Administration Schedule — 1894; 4221; 1773; 5623…
Heart Failure · Myocardial Ischemia · Angina Pectoris
Primary: Participants Stopping Exercise Treadmill Test 3 (ETT-3) for Angina at Stage Earlier Than Baseline Exercise Treadmill Test (ETT-B) — 0; 0; 1 Participants
Congenital Heart Disease
Primary: Mean Arterial Lactate Level — 1.4; 1.4 mmol/L
Measles · Mumps · Rubella
Primary: Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥120 mIU/mL — 741; 383; 124 Participants
Early-Stage Parkinson's Disease
Primary: Number of Subjects With at Least One Adverse Event During This Open-label Extension Study — 214 Subjects
Breast Neoplasms
Primary: Number of Subjects With Clinical Benefit — 24; 24 participants
Nerve Pain
Primary: Change From Baseline to Treatment Week 2 in Daily Pain Rating Scale — 6.03; 5.24; 5.96; 5.31 scores on scale
Menorrhagia · Heavy Menstrual Bleeding
Primary: Mean Reduction From Baseline in Menstrual Blood Loss (MBL) — 65; 44; 7 mL
Chronic Myeloid Leukemia · Philadelphia-Positive Myeloid Leukemia
Primary: Number of Imatinib-resistant Participants With Major Cytogenetic Response (MCyR) — 159 Participants
Attention Deficit Disorder With Hyperactivity
Primary: Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs) — 7; 8; 126; 0 participants
Prostatic Neoplasms
Primary: Percentage of Participants With Prostate Specific Antigen (PSA) Response — 56.4 percentage of participants